Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

TriSalus Life Sciences (TLSIW) Operating Leases (2022 - 2025)

TriSalus Life Sciences' Operating Leases history spans 4 years, with the latest figure at $1.2 million for Q4 2025.

  • For Q4 2025, Operating Leases fell 7.6% year-over-year to $1.2 million; the TTM value through Dec 2025 reached $1.2 million, down 7.6%, while the annual FY2025 figure was $1.2 million, 7.6% down from the prior year.
  • Operating Leases reached $1.2 million in Q4 2025 per TLSIW's latest filing, roughly flat from $1.2 million in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $1.6 million in Q4 2022 to a low of $1.2 million in Q2 2024.
  • Average Operating Leases over 4 years is $1.3 million, with a median of $1.3 million recorded in 2025.
  • Peak YoY movement for Operating Leases: decreased 21.91% in 2023, then rose 14.26% in 2024.
  • A 4-year view of Operating Leases shows it stood at $1.6 million in 2022, then dropped by 21.91% to $1.2 million in 2023, then increased by 6.83% to $1.3 million in 2024, then fell by 7.6% to $1.2 million in 2025.
  • Per Business Quant, the three most recent readings for TLSIW's Operating Leases are $1.2 million (Q4 2025), $1.2 million (Q3 2025), and $1.3 million (Q2 2025).